When Insurance Covers CGM: What Happens to Access and Blood Sugar Control?

Continuous glucose monitors (CGMs) are powerful tools for people with Type 1 diabetes. Research has long shown that they improve blood sugar control and reduce dangerous low blood sugar episodes. Yet many people still don't use them—and cost is often the reason why. A new study looked at what happens when that financial barrier disappears.

Researchers in Turkey examined children and adolescents with Type 1 diabetes before and after their country introduced national reimbursement for CGMs. The results were striking: CGM use jumped from 26% of patients to 92% in just one year. When insurance covers the cost, far more young people can actually use the technology.

The study also tracked what happened to their blood sugar control. Average HbA1c levels (a measure of blood sugar over three months) dropped slightly, from 9.08% to 8.99%. Among children under 10 years old, the group achieving target blood sugar levels below 7% more than doubled, from 16% to 33%. Additionally, there was a trend toward fewer low blood sugar episodes and fewer emergency department visits.

These findings highlight an important distinction: removing a financial barrier didn't just improve blood sugar numbers—it accomplished something crucial first: getting technology to people who needed it. The most significant change was access itself.

The improvements in blood sugar control were real but modest, especially in the overall group. This suggests that access is necessary but not sufficient on its own. Getting a CGM into someone's hands is an important first step, but how well it works also depends on other factors like education, support, and the time it takes for patients and families to learn to use the technology effectively.

This research adds to growing evidence that financial barriers are a major reason some people don't benefit from CGM technology. When reimbursement happens, adoption can increase dramatically. For healthcare systems considering similar policies, the takeaway is clear: covering CGM removes a primary obstacle to access.

At the same time, the study suggests that reimbursement alone isn't a complete solution. Ensuring people have access to devices, training, and ongoing support will likely matter as much as the financial piece in turning technology into better health outcomes.

Source: Acta diabetologica. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.